Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

ere observed. Two events of clinically asymptomatic Grade 3 QTc prolongation occurred in two of four patients enrolled at the 350 mg dose when read by machine. On manual re-read these events were determined to be Grade 2. The dose of 300 mg was declared to be the MTD when administered daily.

The adverse event profile in phase 2 was consistent with phase 1: the most common adverse events were Grade 1 and 2 diarrhea, rash, fatigue, and nausea. Clinically asymptomatic QTc prolongation was also observed.

About the Phase 2 Trial of XL647 as First-Line Therapy

This open-label phase 2 trial is ongoing in previously untreated patients with stage IIIB or IV NSCLC who have adenocarcinoma histology and meet one of the following three criteria: Asian descent, female gender, or no or minimal smoking history. XL647 is administered orally at a dose of 350 mg on Days 1-5 of repeated 14-day cycles. The trial is designed to enrich for patients with activating mutations in the EGF receptor (EGFR) which have been associated with improved sensitivity to other EGFR inhibitors. Based on the selection criteria, Exelixis anticipates that approximately 30 percent of subjects in the trial will have activating EGFR mutations. This design should allow the accumulation of data for patients with and without EGFR mutations, helping to identify those patients most likely to benefit from treatment with XL647.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability, demonstrates excellent activity in target-specific cellular functional assays, and has shown sustained inhibition of target RTKs in vivo in preclinical models following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exe
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... VALLEY, Pa. , Sept. 22, 2014 /PRNewswire/ ... delivering innovative solutions for medical and surgical procedures, ... reached a deal with Munich ... of Kick ® Navigation. This agreement applies ... distribution for cross-disciplinary U.S. sales and all distribution ...
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... Sept. 22, 2014  Sutro Biopharma today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Sutro has earned ... as well as industry partners for what promises to ... bispecifics," says John Carroll , editor of ...
Breaking Medicine Technology:Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... of Cimzia® (certolizumab pegol; CZP) to current therapy ... function and reduced disease activity in a diverse ... those seen in daily clinical practice (including those ... data were presented during the American College of ...
... CryoLife, Inc. (NYSE: CRY ), an ... today that it will participate in the Lazard Capital Markets ... New York City. Steven G. Anderson, president and ... Tuesday, November 16, 2010 at 4:10 p.m., Eastern Time. ...
Cached Medicine Technology:New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:9/22/2014)... September 22, 2014 Locating the top ... is now easier using the Quotes Pros portal online. ... to local universal life insurance pricing from different companies ... plans that are easily viewed when using the finder ... lengths of coverage. The plan data can be reviewed ...
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
(Date:9/22/2014)... a whole eye transplant seems futuristic, if not ... U.S. Department of Defense, researchers at University of ... someday make implantation of an entire, functional eye ... be a holy grail for vision restoration," said ... grant co-recipient with colleagues at University of Pittsburg ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... 2014 The Workgroup for ... nonprofit authority on the use of health IT ... findings from its recent industry survey on the ... within electronic transactions adopted under the Health Insurance ... survey from August 20 to September 5, which ...
Breaking Medicine News(10 mins):Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... to increase participation in the USDA,s Summer Food ... Solutions Minnesota and Second Harvest Heartland today announced ... Children,s Fund Summer Lunch Program ( ... 200,000 additional meals for Minnesota children this summer. ...
... Minneapolis-based Courage Center, a nonprofit rehabilitation and resource center, is ... weeks to Friday, June 12, 2009:, , ... Phillips Awards are presented each year by Courage Center to people ... Three people will be recognized for this employment award and receive ...
... who receive one of the standard treatments for localized prostate ... outcome. , But for the small group whose prostate ... treatment isn,t effective. , The study a collaboration ... Ford Hospital and Fox Chase Cancer Center shows that ...
... Journalists to Examine Health Policy Issues In-depthMENLO ... Family Foundation today announced the nine journalists ... Media Fellowships in Health program. The ... will engage in group site visits focused ...
... With the recent news that one in three common cancers may be ... find it is easier in summer to change their lifestyles than during ... overall health and fight against cancer - inside and out. , ... ...
... Dr. Peter Burrows from the Arizona Center-Vasectomy/Urology, a specialist in ... Seminar on Saturday June 6th. The program, to be ... the latest treatment options for two of the most common ... Enlarged Prostate) and Erectile Dysfunction. A question and answer ...
Cached Medicine News:Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 4Health News:Deadline Extended for Nominations for Jay and Rose Phillips Awards and Phillips Caregiver Award 2Health News:Why some prostate cancer returns 2Health News:Nine Journalists Named as 2009 Kaiser Media Fellows 2Health News:Nine Journalists Named as 2009 Kaiser Media Fellows 3Health News:Nine Journalists Named as 2009 Kaiser Media Fellows 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 2Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 3Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 5Health News:Enlarged Prostate and Erectile Dysfunction Are Subjects of Free Men's Health Seminar 2
... ideal video magnification solution for flexibility ... camera attached to a small flexible ... a mini xY reading table designed ... Minimates versatility allows you to easily ...
... and portability together in one product. Flipperport ... resolution color camera that captures the image, ... display the magnified image. This self contained, ... use and comfort. FlipperPort can easily connect ...
... full-color, auto-focus, desktop video magnifier. Designed with ... enables the user to view images in ... positive or high contrast negative. The first ... enables the user to use simple voice ...
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
Medicine Products: